Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

After reporting non-statistically significant results in it a phase-II study, Cambridge, Mass.-based Seres Therapeutics is launching a revised phase-II study for its SER-109 Clostridium Difficile ...

A new study on Clostridioides difficile infections finds that choosing an alternative antibiotic for high-risk patients with pneumonia can reduce infection risk. C. diff infections can be deadly, and ...

Seres Therapeutics reported results from an interim phase 2 trial for its colon infection treatment weren’t found to be statistically significant. 1. The treatment, SER-109, is intended for multiply ...

Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome. The decline in share price ...

A new study from the University of Birmingham has shown that Faecal Microbiota Transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C.diff) infection. Published ...

Researchers from the University of Virginia in Charlottesville have discovered a type of gut bacteria that could prove effective where other types of helpful bacteria have failed in the fight against ...

SALT LAKE CITY – Over the past two decades there has been a sharp rise in the number and severity of infections caused by the bacteria Clostridium difficile often shortened to C. diff now the most ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed. Conclusion ...

The case could represent the first known instance of cat-to-human transmission of recurrent C. diff, though more research is needed to confirm this risk. Reading time 3 minutes A woman’s newly adopted ...

In developing a treatment for Clostridium difficile—an infection that can cause life-threatening diarrhea—Ferring Pharmaceuticals has had to dig deep in a decadelong pursuit, experimenting with ...